Manifestaciones extraintestinales y comorbilidades en la enfermedad inflamatoria intestinal

  1. Miriam Bragado Pascual 1
  2. Ignacio Marín Jiménez 2
  3. F. Bighelli 1
  1. 1 Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, España
  2. 2 Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, Españ
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2024

Título del ejemplar: Enfermedades del aparato digestivo (VIII) Enfermedad inflamatoria del tubo digestivo

Serie: 14

Número: 8

Páginas: 433-443

Tipo: Artículo

DOI: 10.1016/J.MED.2024.04.015 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Inflammatory bowel disease (IBD) is a systemic disease that can affect different organs and systems in addition to the gastrointestinal tract, generating what are defined as extraintestinal manifestations (EIM) of IBD. This term encompasses a very heterogeneous group of diseases that are usually classified into four groups: classical (directly related to inflammatory activity in the extraintestinal area), systemic consequences of inflammatory activity, complications of treatments, and IBD-associated conditions. The pathophysiology is different for each of them, but they usually share an inflammatory underpinning related to the IBD itself. It is a frequent complication present in up to 50% of patients with IBD and up to 30%–40% of patients present with more than one EIM. It is essential to know these conditions in order to diagnose them early since, in many cases, they have a specific treatment and require a multidisciplinary approach according to the affected organs.

Referencias bibliográficas

  • 1. G. Rogler et al. Extraintestinal manifestations of inflammatory bowel disease: Current concepts, treatment, and implications for disease management Gastroenterology. (2021)
  • 2. A.J. Grant et al. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease) Hepatology. (2001)
  • 3. J.R.C. Miller et al. Inflammatory eye disease: An overview of clinical presentation and management Clinical Medicine. (2022)
  • 4. D.R. Anderson et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients Blood Adv. (2019)
  • 5. T.L. Ortel et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism Blood Adv. (2020)
  • 6. D. Schleiermacher et al. Pulmonary abnormalities in inflammatory bowel disease J Crohns Colitis. (2007)
  • 7. H. Gordon et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease J Crohns Colitis. (2024)
  • 8. S.R. Vavricka et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the swiss inflammatory bowel disease cohort Inflamm Bowel Dis. (2015)
  • 9. C.R.H. Hedin et al. The pathogenesis of extraintestinal manifestations: Implications for IBD research, diagnosis, and therapy J Crohns Colitis. (2019)
  • 10. T. Greuter et al. Extraintestinal manifestations in inflammatory bowel disease-epidemiology, genetics, and pathogenesis Expert Rev Gastroenterol Hepatol. (2019)
  • 11. J.J. Ashton et al. NOD2 in Crohn's disease-unfinished business J Crohns Colitis. (2023)
  • 12. H. Peeters et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease Ann Rheum Dis. (2004)
  • 13. F.M. Jansen et al. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes United European Gastroenterol J. (2020)
  • 14. L. Peyrin-Biroulet et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease Clin Gastroenterol Hepatol. (2017)
  • 15. C. De Galan et al. The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: A real-life multicentre cohort study J Crohns Colitis. (2022)
  • 16. E.J. Brenner et al. Diagnosis and treatment of dermatologic diseases in inflammatory bowel disease Curr Opin Gastroenterol. (2019)
  • 17. V. States et al. Pyoderma gangrenosum in inflammatory bowel disease: A systematic review and meta-analysis Dig Dis Sci. (2020)
Fuente de los datos: Dialnet